The purpose of this research was to formulate and evaluate Ophthalmic In situ gel of Brinzolamide. The main objective of the present study was to increase the Precorneal retention for prolonging the release of drug. A drug delivery system for antiglaucomic agent Brinzolamide was developed utilizing concepts of sustained release, in order to obtain a unique drug delivery system which could remain in the precorneal surface of the eye for a longer period of time. For the development of ophthalmic in situ gel of anti glaucomic agent Brinzolamide, polymers used were HPMC E50LV as a viscosity enhancer and Sodium Alginate as a gelling agent. Disodium Hydrogen Phosphate and citric acid were used as buffer salts. The ophthalmic in situ gel was evaluated for various parameters such as gelling capacity, pH, Viscosity, % drug content and % in vitro drug release profile showed the satisfactory results for all the parameters. The optimized batch showed best gelling capacity, 99.3�±2.21% drug content and 98.03�±3.28 cumulative % drug release over 8 hr. Thus the ophthalmic in situ gel of anti glaucomic agent Brinzolamide was successfully formulated to obtain precorneal retention as well as prolong release of the drug.
Loading....